Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double-blind placebo-controlled trial

Psychiatry Research

Volumn 179, Issue 1, 2010, Pages 19-23

  Iancu, Iulian ^a   Tschernihovsky, Eleonora ^a   Bodner, Ehud ^b   Piconne, Anna Sapir ^a   Lowengrub, Katherine ^a  

^a SHALVATA MENTAL HEALTH CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

Antidepressants; Depression; Escitalopram; Negative symptoms; Placebo controlled; Schizophrenia

Indexed keywords

ESCITALOPRAM; PLACEBO; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD PRESSURE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HUMAN; MALE; MENTAL PATIENT; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; CHRONIC DISEASE; CITALOPRAM; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955429638     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.04.035     Document Type: Article

References (26)

1. Ames D., Marder S.R., Wirshing W.C. The long-term treatment of schizophrenic disorders. Bailliere's Clinical Psychiatry 1995, 1:511-532.
2. Buchanan R.W., Kirkpatrick B., Bryant N., Ball P., Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. American Journal of Psychiatry 1996, 153(12):1625-1627.
3. Burke W.J., Gergel I., Bose A. Fixed-dose trial of the Single isomer SSRI escitalopram in depressed outpatients. Journal of Clinical Psychiatry 2002, 63:331-336.
4. Carpenter W., Buchanan R. Schizophrenia: a review. The New England Journal of Medicine 1994, 330:681-688.
5. Gorman J.M., Korotzer A., Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 2002, 7(suppl 1):40-44.
6. Hiemke C., Peled A., Jabarin M., Hadjez J., Weigmann H., Härtter S., Modai I., Ritsner M., Silver H. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. Journal of Clinical Psychopharmacology 2002, 22(5):502-506.
7. Jockers-Scherübl M.C., Bauer A., Godemann F., Reischies F.M., Selig F., Schlattmann P. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. International Clinical Psychopharmacology 2005, 20(1):27-31.
8. Kasckow J.W., Mohamed S., Thallasinos A., Carroll B., Zisook S., Jeste D.V. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. International Journal of Geriatric Psychiatry 2001, 16(12):1163-1167.
9. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatric Research 1989, 30(2):119-123.
10. Kirkpatrick B., Kopelowicz A., Buchanan R.W., Carpenter W.T. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 2000, 22(3):303-310.
11. Lee M.S., Kim Y.K., Lee S.K., Suh K.Y. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. Journal of Clinical Psychopharmacology 1998, 18(5):399-403.
12. Makinen J., Miettunen J., Isohanni M., Koponen H. Negative symptoms in schizophrenia: a review. Nordic Journal of Psychiatry 2008, 27:1-8.
13. Mulholland C., Lynch G., King D.J., Cooper S.J. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. Journal of Psychopharmacology 2003, 17(1):107-112.
14. Rummel C., Kissling W., Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophrenia Research 2005, 80(1):85-97.
15. Rummel C., Kissling W., Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews 2006, 19(3):CD005581.
16. Salokangas R.K., Saarijärvi S., Taiminen T., Kallioniemi H., Lehto H., Niemi H. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatrica Scandinavica 1996, 94(3):175-180.
17. Sepehry A.A., Potvin S., Elie R., Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. Journal of Clinical Psychiatry 2007, 68(4):604-610.
18. Silver H., Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biological Psychiatry 1992, 31(7):698-704.
19. Silver H., Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. Journal of Clinical Psychopharmacology 1998, 18:208-211.
20. Silver H., Barash I., Aharon N., Kaplan A., Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. International Clinical Psychopharmacology 2000, 15:257-261.
21. Silver H., Nassar A., Aharon N., Kaplan A. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. International Clinical Psychopharmacology 2003, 18(2):87-92.
22. Spina E., De Domenico P., Ruello C., Longobardo N., Gitto C., Ancione M., Di Rosa A.E., Caputi A.P. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. International Clinical Psychopharmacology 1994, 9(4):281-285.
23. Takashi H., Sugita T., Higuchi H., Shimizu T. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. Human Psychopharmacology 2002, 17:95-98.
24. Whitehead C., Moss S., Cardno A., Lewis G. Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews 2002, 2:CD002305.
25. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health 2009. ATC/DDD Index 2009. http://www.whocc.no/atc_ddd_index/_addressed_at1/9/2009.
26. Zisook S., Kasckow J.W., Golshan S., Fellows I., Solorzano E., Lehman D., Mohamed S., Jeste D.V. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. Journal of Clinical Psychiatry 2009, 70(4):562-571.